Explanations:The Sputnik V vaccine is a significant development in the global effort to combat the COVID-19 pandemic. It was developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow, Russia. The vaccine is named after the first artificial satellite, Sputnik, which was launched by the Soviet Union in 1957, marking a significant milestone in space exploration and scientific achievement.
The Sputnik V vaccine uses a two-vector heterologous platform, which means it uses two different adenovirus vectors to deliver the genetic material of the SARS-CoV-2 spike protein. This approach is designed to enhance the immune response and provide long-lasting protection against the virus. The first dose uses adenovirus type 26 (Ad26), and the second dose uses adenovirus type 5 (Ad5). This two-dose regimen is administered with a three-week interval between doses.
Understanding the origin and naming of vaccines is crucial for students preparing for competitive exams, as questions related to vaccine development and their origins are common in general knowledge sections. The Sputnik V vaccine is a notable example of a vaccine developed by a specific country, and its name is derived from a significant historical event in Russian history. This connection between the vaccine and the historical context helps in remembering the name and its origin.
It is important to distinguish between different vaccines and their origins. For instance, Covishield, which is the name of the AstraZeneca vaccine produced in India, and Covaxin, an Indian vaccine developed by Bharat Biotech, are not Russian vaccines. Similarly, Cowin is not a vaccine but a digital platform used in India for managing the vaccination drive. These distinctions are essential to avoid confusion and to correctly identify the origin of each vaccine.